Maxwell Karen L, Bona Diane, Liu Chengsong, Arrowsmith Cheryl H, Edwards Aled M
Ontario Cancer Institute and Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2M9, Canada.
Protein Sci. 2003 Sep;12(9):2073-80. doi: 10.1110/ps.0393503.
Low in vivo solubility of recombinant proteins expressed in Escherichia coli can seriously hinder the purification of structural samples for large-scale proteomic NMR and X-ray crystallography studies. Previous results from our laboratory have shown that up to one half of all bacterial and archaeal proteins are insoluble when overexpressed in E. coli. Although a number of strategies may be used to increase in vivo protein solubility, there are no generally applicable methods, and the expression of each insoluble recombinant protein must be individually optimized. For this reason, we have tested a generic denaturation/refolding protein purification procedure to assess the number of structural samples that could be generated by using this methodology. Our results show that a denaturation/refolding protocol is appropriate for many small proteins (<or=18 kD) that are normally soluble in vivo. In addition, refolding the purified proteins by using dialysis against a single buffer allowed us to obtain soluble protein samples of 58% of small proteins that were found in the insoluble fraction in vivo, and 10% of the initial number of proteins provided good heteronuclear single quantum coherence (HSQC) NMR spectra. We conclude that a denaturation/refolding protocol is an efficient way to generate structural samples for high-throughput studies of small proteins.
在大肠杆菌中表达的重组蛋白在体内的低溶解度会严重阻碍用于大规模蛋白质组核磁共振和X射线晶体学研究的结构样品的纯化。我们实验室之前的结果表明,在大肠杆菌中过表达时,所有细菌和古细菌蛋白中有多达一半是不溶的。尽管可以使用多种策略来提高体内蛋白质的溶解度,但没有普遍适用的方法,每种不溶性重组蛋白的表达都必须单独优化。因此,我们测试了一种通用的变性/复性蛋白质纯化程序,以评估使用该方法可以产生的结构样品数量。我们的结果表明,变性/复性方案适用于许多在体内通常可溶的小蛋白(≤18 kD)。此外,通过对单一缓冲液进行透析来复性纯化的蛋白质,使我们能够获得58%在体内不溶部分中发现的小蛋白的可溶性蛋白质样品,并且10%的初始蛋白数量提供了良好的异核单量子相干(HSQC)核磁共振谱。我们得出结论,变性/复性方案是为小蛋白的高通量研究生成结构样品的有效方法。